The startup specializes in molecular diagnostics by developing biomarkers through bioinformatics technology to enable precise disease risk analysis and targeted drug development. This approach enhances the accuracy of disease diagnosis for healthcare professionals, facilitating personalized treatment strategies.
Funding
$7.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for disease risk analysis and drug development often lack the precision needed for personalized treatment strategies, leading to inefficiencies in healthcare and drug development processes. Traditional diagnostic approaches may not accurately identify patients who would benefit most from specific therapies.
Solution
NOBO Medicine leverages bioinformatics technology to develop biomarkers for precise disease risk analysis and targeted drug development, particularly in oncology and chronic diseases. By focusing on biomarker-driven approaches, the company aims to enhance the accuracy of patient selection for clinical trials and treatment, ensuring that the most suitable patients receive the most effective therapies. Their approach is designed to address unmet medical needs by developing novel therapeutics and diagnostic tools that enable personalized medicine. The company focuses on identifying biomarkers that can predict patient response to specific drugs, allowing for more informed treatment decisions.
Target Audience
The primary target audience includes healthcare professionals seeking more accurate diagnostic tools, pharmaceutical companies aiming to improve drug development efficiency, and patients who could benefit from personalized treatment strategies.
Features
- Development of novel biomarkers for disease risk stratification.
- Bioinformatics-driven approach to identify drug targets and predict patient response.
- Focus on oncology and chronic diseases with unmet medical needs.
- Clinical information-based patient selection for drug development.